MediPost Applies for Phase 3 Clinical Trial Plan of 'EVA-001' for Osteoarthritis in Japan

[Asia Economy Reporter Minji Lee] Medipost announced on the 2nd that it has applied for a CTN for the Phase 3 clinical trial of EVA-001 (CartiSM) in Japan, targeting patients with knee osteoarthritis.

The company stated, "This is to compare the efficacy and safety between a single administration group of EVA-001, an allogeneic umbilical cord blood-derived mesenchymal stem cell, and a hyaluronic acid formulation control group in patients with K&L Grade 2 or 3 knee osteoarthritis," adding, "It will be used for the development of osteoarthritis treatments through not only functional improvement and pain relief but also regeneration of damaged knee cartilage."